Amplitude Unveils New Experimentation Application for Digital Optimization
10.6.2021 12:54:00 EEST | Business Wire | Press release
Amplitude’s Virtual Digital Disruptors Summit — Amplitude, the Digital Optimization System, today introduced Amplitude Experiment, the industry’s first experimentation solution powered by customer behavior and product analytics. Amplitude Experiment provides organizations an end-to-end experimentation and delivery workflow that integrates customer data into every step from generating a hypothesis to targeting users to measuring results. Organizations are empowered to run higher impact A/B tests and remotely configure experiences for key segments without incremental engineering work.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210610005437/en/
New Amplitude Experiment product leverages customer behavior and product analytics to eliminate the barriers to scaling A/B testing programs (Graphic: Business Wire)
“Every company needs to be digital first, but too many are guessing what they should build next and wasting time on experiments that are doomed to fail,” said Justin Bauer, SVP Product, Amplitude. “Since Experiment is powered by customer behavior, businesses can free themselves from low-impact activities and get the invaluable insight that can accelerate and truly scale how they design and deliver digital products and experiences. This is an entirely new chapter for A/B testing that enables any company - whether they’re digital native or embarking on their digital transformation journey - to make bigger and smarter bets that drive stronger business results.”
Digital growth and customer loyalty are driven by how quickly organizations can determine and deliver the best experience for customers. However, existing solutions for A/B testing and feature flagging make it difficult to scale experimentation and rapid learning because they are disconnected from customer behavior. This gap means they lack both the analytics to design effective experiments and surface clear next steps and the behavioral data to target segments and manage user identity. The result is organizations get stuck in low-value activities that don’t drive growth - like testing small tweaks to copy and color changes or using basic on/off toggling to manage new feature release risk - or they waste resources and time on experiments that are doomed to fail - like starting from a weak hypothesis or not being able to reach the right segments.
Through the Behavioral Graph and Amplitude’s Digital Optimization System, Amplitude Experiment eliminates these challenges by resolving the underlying issues of experiment design, targeting, identity resolution and analysis. Now with the addition of the Amplitude Experiment solution, organizations have a complete learning and growth loop from insight to action to testing and delivery all within a single system.
- Amplitude Analytics identifies problems, uncovers opportunities, and measures impact.
- Amplitude Recommend matches the right messages, content, and items to each individual user.
- Amplitude Experiment tests bets and serves the best experience to customers.
“Our digital experience is core to the success of our business - the speed at which we experiment and test new features is critical. Amplitude Experiment is a game changer for Shift. Since it’s powered by customer behavior insights and analytics, we’re able to design better tests, learn from them faster and change the way we build and deliver experiences to our customers”, said Adam Johnston, Director of Product at Shift. “Amplitude has been a great partner to Shift on product analytics, and we are excited to have been able to deepen that relationship through the new Experiment product.”
Experiment is available now. To learn more please visit: amplitude.com/amplitude-experiment and to watch a short video visit: https://www.youtube.com/watch?v=eV4LAKXutqw
About Amplitude
Amplitude is the Digital Optimization System. Powered by the proprietary Amplitude Behavioral Graph, the Digital Optimization System enables organizations to see and predict which combination of features and actions translate to business outcomes — from loyalty to lifetime value — and intelligently adapt each experience in real time based on these insights. Amplitude is the brain behind more than 45,000 digital products at over 1,000 enterprise customers, including 23 of the Fortune 100, helping them innovate faster and smarter by answering the strategic question: “How do our digital products drive our business?” Learn more at https://amplitude.com/.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210610005437/en/
Contact information
Kerry Rothery
Clarity PR for Amplitude
press@amplitude.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Niagen Bioscience Receives Exclusive U.S. FDA Rare Pediatric Disease (RPD) Designation and European Medicines Agency Orphan Medicinal Product Designation (OMPD) for NB4168 for the Treatment of Ataxia Telangiectasia (A-T)13.7.2026 15:32:00 EEST | Press release
Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that the U.S. Food & Drug Administration (FDA) granted Rare Pediatric Disease (RPD) Designation for its proprietary lead small molecule drug candidate NB4168 for the treatment of Ataxia Telangiectasia (A-T). NB4168 is an oral small molecule therapy engineered to deliver substantially greater nicotinamide riboside (NR) exposure than conventional NR while maintaining a differentiated pharmacokinetic and safety profile. In addition, the European Medicines Agency (EMA) has granted Orphan Medicinal Product Designation (OMPD) to NB4168 for the treatment of A-T, providing regulatory recognition in the European Union and further supporting the Company's plans to advance the program globally. The FDA granted RPD Designation based on its determination that A-T is a serious and life-threatening disease that primarily affects individ
Esri Introduces ArcGIS Velocity for ArcGIS Enterprise to Power Real-Time GIS Operations13.7.2026 15:00:00 EEST | Press release
Esri, the global leader in location intelligence, has released for general availability ArcGIS Velocity for ArcGIS Enterprise for self-hosted deployments on Windows and Linux. This enables organizations to leverage Velocity from secure on-premises and private cloud environments. Available as software as a service (SaaS) for ArcGIS Online and now for self-hosted environments in ArcGIS Enterprise, Esri’s next-generation geospatial capability delivers real-time analytics on streaming, Internet of Things (IoT), sensor, and asset data. It helps organizations track and visualize public events, supply chains, and infrastructure to identify and respond to potential threats. ArcGIS Velocity for ArcGIS Enterprise expands cloud-native support to enterprise customers across industries in government and business that rely on firewall protection and internal security compliance. ArcGIS Velocity connects to more than 20 ready-to-use feeds for real-time data providers, including Dataminr, Samsara, Fli
HistoSonics Receives CE Mark, Unlocking Access Across Europe and Accelerating Global Commercialization of the Edison® Histotripsy Platform13.7.2026 15:00:00 EEST | Press release
HistoSonics, today announced that the company has received CE Mark approval in Europe for its Edison® System, enabling commercialization of the company’s non-invasive histotripsy technology in Europe and other markets that recognize the CE Mark. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260713505048/en/ HistoSonics Edison® Histotripsy System The Edison System is a novel, non-invasive, image guided platform that is intended for the destruction of liver tumors, including the partial or complete destruction of unresectable liver tumors. It uses the mechanical properties of focused ultrasound, called histotripsy, to liquefy and destroy unwanted tissue and tumors in a single procedure without the need for invasive procedures or radiation, and with potentially fewer side effects than traditional therapies. CE Mark approval follows an increasing number of regulatory clearances and was supported by a growing body of clinical ev
SLB OneSubsea Awarded EPC Contract for Eni’s Baleine Phase 3 Project Offshore Côte d'Ivoire13.7.2026 15:00:00 EEST | Press release
Global energy technology company SLB (NYSE: SLB) announced today that its OneSubsea™ joint venture has been awarded a major multi-well engineering, procurement, and construction (EPC) contract by Eni for Phase 3 of the deepwater Baleine project offshore Côte d’Ivoire. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260712734539/en/ SLB OneSubsea™ joint venture has been awarded a major multi-well engineering, procurement, and construction (EPC) contract by Eni for Phase 3 of the deepwater Baleine project offshore Côte d’Ivoire. Under the contract, SLB OneSubsea will deliver complete subsea production systems (SPS) for 13 wells, reinforcing its role as a core technology and execution partner on one of the most strategically significant offshore developments currently underway in the region. The EPC scope includes subsea trees, umbilical, manifolds, multiphase flowmeters and control systems, along with installation, commissionin
Agenus Announces Oversubscribed Private Placement of Up to $340 Million to Advance Registrational ROBBIN Trial of Neoadjuvant BOT+BAL in MSS Colon Cancer13.7.2026 13:00:00 EEST | Press release
Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that it has entered into a securities purchase agreement for a private placement of approximately $85 million in upfront gross proceeds, before the deduction of private placement expenses, and up to an additional $255 million upon the full exercise of purchase warrants. The financing was led by Commodore Capital, with participation from RA Capital Management, TCGX, Invus, and Ligand Pharmaceuticals. The net proceeds of this financing are expected to support Agenus’ strategic prioritization of botensilimab and balstilimab (BOT+BAL) for the neoadjuvant treatment of microsatellite-stable (MSS) colon cancer, including advancement of ROBBIN1, the Company’s planned registrational Phase 3 neoadjuvant trial in microsatellite-stable (MSS) colon cancer. High-risk Stage II and Stage III MSS colon cancer affect an estimated 38,000 patients annually in the US and more than 200,000 patients worldwide,2 representing a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom